On the stock market since 2025, it operates in the world of health and science. It has 2 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $3.2M against $0 in annual sales.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, TTRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TTRX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.